Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Genedrive ( (GB:GDR) ) is now available.

Genedrive plc announced the national rollout of its Genedrive® MT-RNR1 ID Kit in Scotland, aimed at preventing hearing loss in newborns by providing rapid genetic testing in neonatal units. Funded by the Scottish Government and supported by NHS Greater Glasgow and Clyde, the rollout will cover all territorial health boards over 18 months. This initiative is part of a broader effort to integrate innovative genetic testing into standard clinical practice, enhancing neonatal care and personalized treatment. The rollout is expected to impact over 3,000 newborns in its first year, marking a significant advancement in neonatal healthcare in Scotland.

The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.

Spark’s Take on GB:GDR Stock

According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.

Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.

To see Spark’s full report on GB:GDR stock, click here.

More about Genedrive

Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercializes rapid, low-cost, and easy-to-use point-of-care pharmacogenetic platforms. These platforms assist clinicians in making informed decisions about medication choices and dosages, particularly in emergency healthcare settings. The company has launched two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both designed to provide quick genetic information to improve patient outcomes. Genedrive focuses on expanding its market presence and product portfolio while operating from its facilities in Manchester.

Average Trading Volume: 6,192,172

Technical Sentiment Signal: Strong Sell

Current Market Cap: £5M

Find detailed analytics on GDR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue